Purpose
To harmonize the use of color for MR relaxometry maps and therefore recommend the use of specific color-maps for representing T1, T2, and T2* maps and their inverses.

Methods
Perceptually linearized color-maps were chosen to have similar color settings as those proposed by Griswold et al. in 2018. A Delphi process, polling the opinion of a panel of 81 experts, was used to generate consensus on the suitability of these maps.

Results
Consensus was reached on the suitability of the logarithm-processed Lipari color-map for T1 and the logarithm-processed Navia color-map for T2 and T2*. There was consensus on color bars being mandatory and on the use of a specific value indicating “invalidity.” There was no consensus on whether the ranges should be fixed per anatomy.

Conclusion
The authors recommend the use of the logarithm-processed Lipari color-map for displaying quantitative T1 maps and R1 maps; likewise, the authors recommend the logarithm-processed Navia color-map for displaying T2, T2*, R2, and R2* maps.

This work originated with the Quantitative MR Study Group of the International Society of Magnetic Resonance in Medicine (ISMRM); it has the approval of the Publication Committee and of the Board of the ISMRM.@en

Presenting quantitative data using non-standardized color maps potentially results in unrecognized misinterpretation of data. Clinically meaningful color maps should intuitively and inclusively represent data without misleading interpretation. Uniformity of the color gradient for color maps is critically important. Maximal color and lightness contrast, readability for color vision-impaired individuals, and recognizability of the color scheme are highly desirable features. This article describes the use of color maps in five key quantitative MRI techniques: relaxometry, diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE)-MRI, MR elastography (MRE), and water-fat MRI. Current display practice of color maps is reviewed and shortcomings against desirable features are highlighted. Evidence Level: 5. Technical Efficacy: Stage 2.

@en

Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.

@en